Sandbox I3DC 007
From Proteopedia
(Difference between revisions)
| Line 7: | Line 7: | ||
This study presents the high-resolution crystal structure of the intracellular domain of <scene name='10/1081088/007_fig_02_new/3'>TGFβR1 in complex with the competitive inhibitor SB505124</scene>. The findings provide detailed insights into this complex's molecular interactions and structural configuration, elucidating the mechanisms by which SB505124 inhibits TGFβR1 activity. These insights are significant for understanding the regulation of TGF-β signaling, a pathway critically involved in cancer biology. | This study presents the high-resolution crystal structure of the intracellular domain of <scene name='10/1081088/007_fig_02_new/3'>TGFβR1 in complex with the competitive inhibitor SB505124</scene>. The findings provide detailed insights into this complex's molecular interactions and structural configuration, elucidating the mechanisms by which SB505124 inhibits TGFβR1 activity. These insights are significant for understanding the regulation of TGF-β signaling, a pathway critically involved in cancer biology. | ||
The manuscript highlights several key points: | The manuscript highlights several key points: | ||
| - | 1. Structural Insights: We reveal the atomic-level <scene name='10/ | + | 1. Structural Insights: We reveal the atomic-level <scene name='10/1081088/Fig_02/2'>interactions between TGFβR1 and SB505124</scene>, offering a comprehensive view of how this inhibitor binds to and affects the receptor's conformation. A comparison of the ICD–SB505124 and ICD–SB431542 complexes is seen in a <scene name='10/1060550/007_fig_3_new_01_png/2'>close-up view</scene>. |
2. Regulatory Mechanisms: The structural analysis sheds light on the functional implications of SB505124 binding, particularly its role in disrupting TGF-β signaling pathways, which are often deregulated in various cancers. | 2. Regulatory Mechanisms: The structural analysis sheds light on the functional implications of SB505124 binding, particularly its role in disrupting TGF-β signaling pathways, which are often deregulated in various cancers. | ||
3. Therapeutic Potential: Based on the structural findings, the potential of SB505124 as a therapeutic agent in cancer treatment is discussed, providing a foundation for future drug development efforts targeting TGFβR1. | 3. Therapeutic Potential: Based on the structural findings, the potential of SB505124 as a therapeutic agent in cancer treatment is discussed, providing a foundation for future drug development efforts targeting TGFβR1. | ||
Revision as of 14:28, 20 May 2025
| |||||||||||
